2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
Broader equities have been fairly resilient this year. However, there remains a very real possibility that macroeconomic problems and geopolitical tensions will eventually lead to a market crash. One way to prepare for that is to invest in dividend stocks with strong underlying businesses. Here are two options investors should consider: Johnson & Johnson (NYSE: JNJ) and Amgen (NASDAQ: AMGN). Both of these dividend payers have outperformed the broader market this year, but can they keep going?
Image source: The Motley Fool.
Missed AI’s “Act 1”? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »
1. Johnson & Johnson
Johnson & Johnson’s financial results have helped power its strong stock market performance this year. However, the company’s latest quarterly update was somewhat mixed. True, Johnson & Johnson’s revenue and earnings came in above expectations. The drugmaker even slightly raised its guidance for the fiscal year 2026.
But that was because of the company’s innovative medicines division. Johnson & Johnson’s medtech unit, particularly its cardiovascular segment, is running into some problems. One of the company’s products, the Impella heart pump, has faced lower demand due to questions surrounding its safety and efficacy — and in the U.S., it has been the subject of a Class 1 recall. Johnson & Johnson is working on these issues.
The company is running clinical trials it hopes will show the effectiveness of the Impella. A success here could improve the Impella’s prospects, but a clinical failure would be a setback for the company. So, will Johnson & Johnson maintain its recent momentum?
My view is that the company’s near-term outlook is somewhat uncertain, largely due to its medtech-related issues. But Johnson & Johnson’s long-term prospects remain intact. Here are four reasons why. First, the innovative medicines segment is only getting better. Johnson & Johnson has launched several new products in recent years, including ICOTYDE for plaque psoriasis, that could help drive strong sales growth over the medium term.
Second, Johnson & Johnson earned U.S. marketing authorization for its OTTAVA robotic-assisted surgery system earlier this year. This device could also become an important growth driver down the line. Third, the company has moved one step closer to putting its talc-based lawsuits behind it with a proposed $5.5 billion settlement. Lastly, there is the company’s outstanding track record of dividends.
Johnson & Johnson is a Dividend King, that is, a corporation with 50 or more years of consecutive annual payout increases (the company’s streak stands at 64). Johnson & Johnson’s dividend appears to be about as safe as they come, especially considering its AAA rating from S&P Global, the highest rating available. The stock may or may not perform well over the next year, but Johnson & Johnson is a great income stock for long-term investors.
2. Amgen
Amgen is performing well despite dealing with multiple headwinds. For instance, the company is facing regulatory pressure regarding Tavneos, a medicine for severe anti-neutrophil cytoplasmic autoantibody-associated vasculitis, which it acquired through its 2022 buyout of ChemoCentryx. The U.S. Food and Drug Administration is pushing to remove Tavneos from the market due to safety risks and insufficient evidence of efficacy. Elsewhere, Amgen lost U.S. patent exclusivity for denosumab, a medicine for some bone-related conditions, last year.
Denosumab was an important growth driver for Amgen, but the medicine’s sales are now falling sharply due to biosimilar competition. Even with these (and other) problems, Amgen’s financial results have been strong. Second-quarter revenue grew 10% year over year to $10.1 billion. However, there is a very real possibility that Amgen will succumb to near-term headwinds and see its stock price decline significantly.
Consider, for instance, that Tavneos generated $150 million in revenue in the second quarter. That’s only 1.5% of the company’s second-quarter sales. But Tavneos’ revenue grew 36% year over year and would be a decent contributor to top-line growth in the medium term, especially as older products lose patent exclusivity. Still, Amgen’s outlook for the next five years looks strong.
Several of the company’s growth drivers are performing very well and will help offset the loss of Tavneos (if it comes to that). The list includes Tezspire, an asthma medicine, and Tepezza, a drug approved to treat thyroid eye disease. Amgen could also earn approval for important new products over the next few years. Perhaps the company’s most promising candidate is MariTide, a GLP-1 medicine being investigated for weight loss and across obesity-related conditions.
MariTide could be administered monthly (or less frequently), offering a highly differentiated option relative to the current weight-loss market leaders. Amgen’s lineup and pipeline are both deep and can withstand regulatory setbacks and patent cliffs, as it has in recent years. Then there is the company’s dividend. Amgen has increased its payouts by 152% over the past decade and offers a forward yield of 2.3%, compared with the S&P 500‘s average of 1.1%. Amgen is another excellent income stock to buy and hold for the long term.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $376,696!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,333,920!*
Now, it’s worth noting Stock Advisor’s total average return is 925% — a market-crushing outperformance compared to 212% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Space Exploration Technologies Corp. (NASDAQ:SPCX) reported its third-quarter earnings after the market closed on Oct. 20, with results that largely topped Wall Street estimates. Here are the key numbers: Missed AI’s “Act 1”? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But
Meta (META) will kick off Big Tech’s earnings season when it reports its third quarter results after the bell on Wednesday. For the third quarter, Meta is expected to post earnings per share of $3.56 on revenue of $63.3 billion, according to Bloomberg analyst consensus estimates. That’s up from the $1.05 and $51.2 billion the
Artificial intelligence (AI) stocks have led this bull market over the past three years, pushing the S&P 500 to record highs. Investors were eager to get in on this promising technology early on, and in many cases, they’ve already greatly benefited. For example, chip designers such as Nvidia and Advanced Micro Devices, as well as
The Morning Bull – US Market Morning Update Tuesday, Oct, 20 2026 US stocks are set for a firmer open, with sentiment leaning risk on as investors focus on a clear upswing in American factory activity. The key driver this morning is stronger than expected industrial and capacity data. Industrial production rose 0.7% month over
This year has been one for the record books, with the S&P 500 (SNPINDEX: ^GSPC), Nasdaq Composite (NASDAQINDEX: ^IXIC), and Dow Jones Industrial Average (DJINDICES: ^DJI) all reaching multiple all-time highs. But what goes up must come down eventually. Bond yields are at their highest levels in decades, raising borrowing costs for consumers and making
Statistically, the stock market has delivered outsize annual returns under President Donald Trump. During his first non-consecutive term (Jan. 20, 2017-Jan. 20, 2021), the Dow Jones Industrial Average (DJINDICES:^DJI), S&P 500 (SNPINDEX:^GSPC), and Nasdaq Composite (NASDAQINDEX:^IXIC) soared 57%, 70%, and 142%, respectively. All three indexes have delivered an encore performance since the start of his
US housing market conditions are unlikely to change much just because the calendar turns from 2026 to 2027, Goldman Sachs warned. Elevated mortgage rates will keep homeownership out of reach for many Americans and, in turn, weigh on the US economy. “In 2027, we expect the headwind from affordability — reignited by the recent rebound
1 Cash-Producing Stock with Competitive Advantages and 2 Facing Challenges A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here is one
Homebuilder confidence slumped to the lowest level since 2012 as builders contend with rising mortgage rates, high materials costs, and a challenging labor market. Confidence in the market for new single-family homes fell three points to 29 in October, according to the latest National Association of Home Builders/Wells Fargo Housing Market Index reading. The last
India’s second-richest man, Mukesh Ambani, is launching what could be the country’s biggest-ever initial public offering (IPO), despite a stock market downturn. Mumbai-based Jio Platforms, a telecoms company backed by Meta Platforms and Google, is hoping to raise up to 302bn rupees (£2.4bn) and is targeting a 10.3tn rupees valuation when it floats on the
GM (GM) posted third quarter results before the bell that topped estimates, tightened its full-year profit outlook instead of boosting it, but issued shareholders a new $20 billion share repurchase program instead. For the quarter, GM posted Q3 revenue of $50.0 billion, up 2.9% from a year ago and above the $48.52 billion Bloomberg consensus.
Quick Read Your IRA balance on December 31 permanently locks in next year’s RMD, so even a January 15% drop still leaves you owing the larger amount. A $1 million IRA at 75 forces a $40,650 RMD even after a drop to $850,000, costing an extra $1,341 in federal taxes. Taking RMDs in shares instead
Netflix (NASDAQ:NFLX) has successfully disrupted the entertainment industry, but lately it looks like it’s the one getting left behind. The stock is down 26% year-to-date, even as the broad market has risen, and Netflix lost out on its planned acquisition of Warner Bros Discovery after it was outbid by Paramount Skydance, which is now Skydance.
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Cryptocurrency bettors aren’t fully bought into Amazon.com Inc. (NASDAQ:AMZN) hitting $300 or higher in October, even as the tech behemoth braces for its third-quarter financial results. Where’s Your Money on? The betting crowd on Polygon (CRYPTO: POL)-based Polymarket
Since it is election season, voters and investors who closely monitor the intersection of financial markets and politics are being inundated with political prognostications often conveyed in “leans/likely/D/R” form. Essentially, those predictions are pundits’ way of saying that a particular result is likely to occur in a specific electoral contest. Sometimes, “probably” is as good
In recent years, investors have closely followed quantum computing. If successful, the technology could increase computing speeds exponentially. The problem with this technology is the delicate nature of quantum bits (qubits) and high error rates. Such challenges mean that widespread commercial viability is likely several years away. Missed AI’s “Act 1”? Act 2 Could Be
Global food prices face pressure from repeated supply shocks, and that matters for Canadian investors. Higher grocery and transport bills quietly punish weak businesses and reward those with strong cash generation and resilient balance sheets. That creates an opening to consider robust Canadian stocks that the market currently prices too cautiously. This article walks through
The world is holding its breath as it waits to find out whether this year’s estimated $US1tn investment in artificial intelligence is resting on a castle made of sand. Last week, the Nasdaq 100 – an index of the 100 biggest non-financial stocks on the American tech-heavy Nasdaq exchange – dropped by 5.5%, triggering the
KOSPI falls 4% as South Korea’s chip-heavy stock index slides. Photo by BeInCrypto The Korea Composite Stock Price Index (KOSPI) fell 3.5% at Tuesday’s open as a chip-led AI sell-off drags on, cutting its 2026 gain to about 31% from roughly 116% at its June record close. The index now sits about 39% below that
